← Back to Search

Viscosupplementation

Synvisc-One for Younger, Active Patients With Osteoarthritis (SYNVISC-ONE Trial)

N/A
Waitlist Available
Led By Anthony Luke, MD
Research Sponsored by Anthony Luke
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 26 weeks post-injection at baseline through 3 years post-injection
Awards & highlights
No Placebo-Only Group

Summary

This study aims to study use of viscosupplementation as a treatment of pain for young individuals who are active. Typically viscosupplementation is considered an intervention for knee osteoarthritis often for older patients who are less active. Many young active patients can also develop knee osteoarthritis after trauma or surgery or for congenital reasons. Treatment of these patients commonly are steroid injections which have more biologically detrimental effects for cartilage compared to viscosupplementation Synvisc One injections which are a single injection will be used to determine effectiveness of reducing pain and maintaining an active healthy lifestyle for younger patients aged 30-50 years old.

Eligible Conditions
  • Osteoarthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~26 weeks post-injection at baseline through 3 years post-injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and 26 weeks post-injection at baseline through 3 years post-injection for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
"Worst Knee Pain" Likert Scale (0-10) Reported on Survey
Secondary study objectives
Identify the Effects of Treatment on Activity Levels
Minimal Clinical Important Improvement (The Effect of Repeated Injections)
Patient Acceptable Symptom Score (The Effect of Repeated Treatments)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Synvisc-OneExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Synvisc-One (G-F 20)
2011
N/A
~60

Find a Location

Who is running the clinical trial?

Anthony LukeLead Sponsor
Anthony Luke, MDPrincipal InvestigatorUniversity of California, San Francisco
~4 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top